External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

NBDF 2024

-
Coming soon
10:30 PM
Duration 1hr Atlanta, USA
Long-Term Follow-Up of Participants in the Phase I/II Trial of Dirloctocogene Samoparvovec (SPK-8011): Durable FVIII Expression and Clinically Meaningful Reduction of Bleeding
George L, Croteau SE, Chang T, Eyster ME, Tran H, Ragni MV, Sullivan S, Rasko JEJ, Moormeier J, Angchaisuksiri P, Teitel J, Kenet G, Wynn T, Samelson-Jones B, Jaeger S, Ramos J, Mingozzi F, Levy G
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar